Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ameile (aumolertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Abdul Latif Jameel Health, Glenmark, Jiangsu Hansoh Pharma

Drug class:

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2